Journal Article (Review Article)

DKFZ-2019-01620

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.

Bretscher, C. (First author)DKFZ* ; Marchini, A. (Last author)DKFZ*

2019
MDPI Basel

This record in other databases:  

Please use a persistent id in citations: doi:10.3390/v11060562

Abstract: The rat protoparvovirus H-1PV is nonpathogenic in humans, replicates preferentially in cancer cells, and has natural oncolytic and oncosuppressive activities. The virus is able to kill cancer cells by activating several cell death pathways. H-1PV-mediated cancer cell death is often immunogenic and triggers anticancer immune responses. The safety and tolerability of H-1PV treatment has been demonstrated in early clinical studies in glioma and pancreatic carcinoma patients. Virus treatment was associated with surrogate signs of efficacy including immune conversion of tumor microenvironment, effective virus distribution into the tumor bed even after systemic administration, and improved patient overall survival compared with historical control. However, monotherapeutic use of the virus was unable to eradicate tumors. Thus, further studies are needed to improve H-1PV's anticancer profile. In this review, we describe H-1PV's anticancer properties and discuss recent efforts to improve the efficacy of H-1PV and, thereby, the clinical outcome of H-1PV-based therapies.

Note: #DKFZ-MOST-Ca184#

---

Contributing Institute(s):

1. LOVIT (F011)

Research Program(s):

1. 316 - Infections and cancer (POF3-316) (POF3-316)

Appears in the scientific report 2019

---

Database coverage:
; ; ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---